- Stocks
- Pharma & Healthcare
- Vikram Thermo
Vikram Thermo share price
NSE: VIKRAMTHPharma & HealthcareDrug Manufacturers - Specialty & Generic
Vikram Thermo at a glance
With a market capitalisation of ₹728 Cr, it ranks 1608th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 6.7% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹38 Cr (+39.3% year on year) and net profit ₹9 Cr (+109.3%), on a standalone basis. Promoters held 66.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹728 CrRank 1608 on NSE
- Price to book
- 4.52×FY25
- EPS (TTM)
- ₹12.28to Q4 FY26
- ROE
- 6.7%FY25
- ROCE
- 35.8%FY25
- Debt to equity
- 0.05FY25
- Net profit margin
- 6.4%FY25
- Book value / share
- ₹38.73FY25
- Dividend payout
- 29.0%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Vikram Thermo quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹31 Cr | ₹34 Cr | ₹34 Cr | ₹27 Cr | ₹29 Cr | ₹35 Cr | ₹34 Cr | ₹38 Cr |
| Revenue YoY | +5.4% | −0.5% | +8.8% | −13.9% | −8.2% | +2.9% | −0.9% | +39.3% |
| Net profit | −₹16 Cr | ₹10 Cr | ₹10 Cr | ₹4 Cr | ₹8 Cr | ₹11 Cr | ₹11 Cr | ₹9 Cr |
| Net profit YoY | −374.8% | +18.7% | +56.4% | −17.4% | — | +13.2% | +8.8% | +109.3% |
| Net margin | −50.8% | 29.1% | 29.3% | 15.0% | 27.8% | 32.0% | 32.2% | 22.6% |
| EPS | −₹5.05 | ₹3.14 | ₹3.21 | ₹1.30 | ₹2.53 | ₹3.53 | ₹3.50 | ₹2.72 |
Vikram Thermo financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹56 Cr | ₹74 Cr | ₹93 Cr | ₹112 Cr | ₹126 Cr | ₹126 Cr |
| Operating profit | ₹9 Cr | ₹16 Cr | ₹12 Cr | ₹23 Cr | ₹34 Cr | ₹44 Cr |
| Net profit | ₹7 Cr | ₹12 Cr | ₹9 Cr | ₹17 Cr | ₹25 Cr | ₹8 Cr |
| EPS (₹) | ₹11.85 | ₹19.24 | ₹13.86 | ₹5.39 | ₹8.09 | ₹2.58 |
| Cash from operations | ₹13 Cr | ₹15 Cr | ₹6 Cr | ₹13 Cr | ₹23 Cr | ₹24 Cr |
| Total debt | ₹3 Cr | ₹7 Cr | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹2 Cr |
| Shareholders' equity | ₹55 Cr | ₹66 Cr | ₹73 Cr | ₹90 Cr | ₹114 Cr | ₹121 Cr |
Vikram Thermo shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 65.94% | 66.00% | 66.00% | 66.00% | 66.01% | 66.01% |
| Domestic institutions | — | — | — | — | — | 0.26% |
| Non-institutions | 34.06% | 34.00% | 34.00% | 34.00% | 33.99% | 33.74% |
Vikram Thermo vs peers
The listed Pharma & Healthcare companies nearest to Vikram Thermo by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ANUHPHRAnuh Pharma | ₹80.29 | +0.68% | +0.4% | ₹805 Cr | 19.6 | — |
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
Ask anything about Vikram Thermo
Pivot answers on the live chart with evidence you can check, and tests strategies against VIKRAMTH's own history. Try: “Why has VIKRAMTH moved over the last three months?” · “Backtest a 50-day moving-average crossover on VIKRAMTH over five years” · “Compare VIKRAMTH with ANUHPHR on margins and valuation”
Frequently asked questions about Vikram Thermo
What is the market cap of Vikram Thermo?
Vikram Thermo's market capitalisation is ₹728 Cr (₹728 Cr) at the 22 Oct 2026 close, ranking 1608th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Vikram Thermo?
Return on equity was 6.7% in FY25 and return on capital employed was 35.8% in FY25 (standalone figures).
Is Vikram Thermo a debt-free company?
Vikram Thermo is close to debt-free: its debt-to-equity ratio was 0.05 in FY25.
What were Vikram Thermo's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Vikram Thermo reported revenue of ₹38 Cr, +39.3% year on year, and net profit of ₹9 Cr, +109.3% year on year.
What is the shareholding pattern of Vikram Thermo?
As of 30 Jun 2026: promoters 66.01%, domestic institutions 0.26%, non-institutions 33.74%.
Who are Vikram Thermo's competitors?
The listed Pharma & Healthcare companies closest to Vikram Thermo by market cap are Anuh Pharma, Kilitch Drugs (India), Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.
Is Vikram Thermo a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vikram Thermo's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIKRAMTH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text